Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 11 of 11 publications.

Poonawalla IB, Bowe AT, Tindal MC, Meah YA, Schwab P. A real-world comparison of cardiovascular, medical and costs outcomes in new users of SGLT2 inhibitors versus GLP-1 agonists. Diabetes Res Clin Pract. 2021 May;175:108800. doi: 10.1016/j.diabres.2021.108800

Graz H, D'Souza VK, Alderson DEC, Graz M. Diabetes-related amputations create considerable public health burden in the UK. Diabetes Res Clin Pract. 2018 Jan;135:158-65. doi: 10.1016/j.diabres.2017.10.030

Bykov K, Bohn RL, Ewenstein BM, Seeger JD, Avorn J, Bateman BT. Use of bypassing agents and risk of thromboembolic events in patients with haemophilia and inhibitors. Thromb Haemost. 2017 Dec;117(12):2267-73. doi: 10.1160/TH17-05-0365

Mazurek M, Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Lu S, Lip GYH, GLORIA-AF Investigators. Regional differences in antithrombotic treatment for atrial fibrillation: insights from the GLORIA-AF phase II registry. Thromb Haemost. 2017 Dec;117(12):2376-88. doi: 10.1160/TH17-08-0555

Lawton J, Kirkham J, Rankin D, Barnard K, Cooper CL, Taylor C, Heller S, Elliott J, Basarir H, REPOSE group. Perceptions and experiences of using automated bolus advisors amongst people with type 1 diabetes: a longitudinal qualitative investigation. Diabetes Res Clin Pract. 2014 Dec;106(3):443-50. doi: 10.1016/j.diabres.2014.09.011

Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.

Lee LJ, Fahrbach JL, Nelson LM, McLeod LD, Martin SA, Sun P, Weinstock RS. Effects of insulin initiation on patient-reported outcomes in patients with type 2 diabetes: results from the DURABLE trial. Diabetes Res Clin Pract. 2010 Aug 1;89(2):157-66.

Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Noack H, Robinson PA, Dolan G, Brenkel IJ. Economic evaluation of dabigatran etexilate for the preventionof venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. Thromb Haemost. 2010 Feb 1;103(2):360-71.

Hoerger TJ, Zhang P, Segel JE, Gregg EW, Venkat Narayan KM, Hicks KA. Improvements in risk factor control among persons with diabetes in the United States: evidence and implications for remaining life expectancy. Diabetes Res Clin Pract. 2009 Dec 1;86(3):225-32.

Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. 2009 Jan 1;101(1):77-85.

Donatti C, Wild D, Horblyuk R, Beusterien KM, Anderson R, Arondekar B, DiBenedetti DB. Psychometric evaluation of the satisfaction with Oral Anti-Diabetic Agent Scale. Diabetes Res Clin Pract. 2008 Apr;80(1):108-13.